Mykafungina Accordpharma (Micafungin)

Micafungin inhibits the enzyme β‑(1,3)‑D‑glucan synthase, which is essential for producing β‑(1,3)‑D‑glucan, a critical structural component of the fungal cell wall. Disruption of cell‑wall synthesis leads to osmotic instability and fungal cell lysis, providing a fungicidal effect.

The dosage regimen is determined by the prescribing clinician based on the specific infection, patient weight, renal and hepatic function, and local treatment guidelines. Physicians select the appropriate strength and duration for each case.

Safety data in pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and it should be prescribed under specialist supervision.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Micafungin belongs to the echinocandin class, which targets the fungal cell wall, whereas azoles inhibit ergosterol synthesis and polyenes bind to membrane sterols. Echinocandins are generally well‑tolerated, have fewer drug‑drug interactions, and are effective against many azole‑resistant Candida species, making them a valuable alternative in resistant or severe infections.

Store at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, direct sunlight and extreme temperatures to maintain stability and potency throughout its shelf life.

The medication is supplied as an oral dosage form and is taken by mouth according to the prescribing clinician’s instructions. It may be taken with or without food, but patients should follow any specific guidance regarding timing relative to meals.

Serious adverse reactions, although rare, include severe hepatic dysfunction, life‑threatening hypersensitivity such as anaphylaxis, and severe cutaneous reactions like Stevens‑Johnson syndrome or toxic epidermal necrolysis. Prompt medical attention is required if any signs of these conditions appear.

Patients with known hypersensitivity to micafungin or any component of the formulation should avoid the product. Caution is also advised for individuals with pre‑existing severe liver disease, and the drug should be used only under medical supervision in such cases.